ARYx Therapeutics Inc
OTC:ARYX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
ARYx Therapeutics Inc
EPS (Diluted)
ARYx Therapeutics Inc
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
ARYx Therapeutics Inc
OTC:ARYX
|
EPS (Diluted)
-$1
|
CAGR 3-Years
8%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
EPS (Diluted)
$8
|
CAGR 3-Years
21%
|
CAGR 5-Years
9%
|
CAGR 10-Years
4%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
EPS (Diluted)
$3
|
CAGR 3-Years
5%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
14%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
EPS (Diluted)
$1
|
CAGR 3-Years
-37%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
2%
|
|
|
Merck & Co Inc
NYSE:MRK
|
EPS (Diluted)
$7
|
CAGR 3-Years
8%
|
CAGR 5-Years
21%
|
CAGR 10-Years
17%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
EPS (Diluted)
$22
|
CAGR 3-Years
49%
|
CAGR 5-Years
28%
|
CAGR 10-Years
26%
|
|
ARYx Therapeutics Inc
Glance View
ARYx Therapeutics, Inc. discovers and develops drugs for large, chronic disease markets. The company is headquartered in Fremont, California and currently employs 56 full-time employees. The company went IPO on 2007-11-08. The firm is developing a proprietary portfolio of patient-targeted, first-in-class monoclonal antibodies designed to treat seriously ill patients with difficult-to-treat diseases. The company is engaged in retrometabolic drug design that focuses on the safety of oral therapies for chronic disease. The Companys clinical compounds include naronapride (ATI-7505) for gastrointestinal disorders; budiodarone (ATI-2042, for the treatment of atrial fibrillation; tecarfarin (ATI-5923) for the treatment of anticoagulation; and ATI-9242, for psychiatric disorders.
See Also
What is ARYx Therapeutics Inc's EPS (Diluted)?
EPS (Diluted)
-1.2
USD
Based on the financial report for Dec 31, 2009, ARYx Therapeutics Inc's EPS (Diluted) amounts to -1.2 USD.
What is ARYx Therapeutics Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
0%
Over the last year, the EPS (Diluted) growth was 27%. The average annual EPS (Diluted) growth rates for ARYx Therapeutics Inc have been 8% over the past three years .
